抗肥胖药物治疗的进展与挑战
肥胖是严重的全球健康挑战,生活方式干预是基础但减重有限且易反弹。多种抗肥胖药物已在美国、欧盟、澳大利亚和日本获批,均可比单纯生活方式改变带来更大减重,但使用率很低,部分源于对安全性和疗效的担忧及保险覆盖不足。医师应能讨论药物风险与获益,保险公司应为最可能获益的患者提供合理覆盖。
要点
- 生活方式干预是肥胖治疗基础,但通常仅产生难以维持的适度减重。
- 已获批抗肥胖药物包括拟交感神经药、胰脂肪酶抑制剂、GABAA受体激活剂、5-羟色胺2C受体激动剂、阿片拮抗剂、多巴胺-去甲肾上腺素再摄取抑制剂和GLP-1受体激动剂。
- 这些药物疗效和副作用不同,但均比单纯生活方式改变带来更大减重。
核心结论
- 抗肥胖药物可帮助减重,但使用率很低,部分因对安全性和疗效的担忧及保险覆盖不足。
- 医师应能自如讨论这些药物的风险与获益,保险公司应为最可能获益的患者提供合理覆盖。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 健康生活方式选择是肥胖治疗的基础。
- 减重可导致促进体重反弹的生理适应,因此单纯生活方式治疗通常仅产生难以维持的适度减重。
- 已获批抗肥胖药物包括拟交感神经药、胰脂肪酶抑制剂、GABAA受体激活剂、5-羟色胺2C受体激动剂、阿片拮抗剂、多巴胺-去甲肾上腺素再摄取抑制剂和GLP-1受体激动剂。
- 这些药物疗效和副作用不同,但均比单纯生活方式改变带来更大减重。
- 肥胖广泛存在且与不良健康后果相关,抗肥胖药物可帮助减重,但极少患者使用这些药物。
临床怎么用
- 医师应能自如讨论这些药物的风险与获益。
- 健康保险公司应为最可能获益的患者提供合理覆盖。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity is a serious and growing worldwide health challenge. Healthy lifestyle choices are the foundation of obesity treatment. However, weight loss can lead to physiological adaptations that promote weight regain. As a result, lifestyle treatment alone typically produces only modest weight loss that is difficult to sustain. In other metabolic diseases, pharmacotherapy is an accepted adjunct to lifestyle. Several anti-obesity drugs have been approved in the USA, European Union, Australia, and Japan including sympathomimetics, pancreatic lipase inhibitors, GABAA receptor activators, a serotonin 2C receptor agonist, opioid antagonist, dopamine-norepinephrine reuptake inhibitor, and glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs vary in their efficacy and side-effect profiles but all provide greater weight loss than do lifestyle changes alone. Even though obesity is widespread and associated with adverse health consequences, and anti-obesity drugs can help people to lose weight, very few patients use these drugs partly because of concerns about safety and efficacy, but also because of inadequate health insurance coverage. Despite great advances in our understanding of the biology of weight regulation, many clinicians still believe that patients with obesity should have the willpower to eat less. The tendency to hold the patient with obesity responsible for their condition can be a barrier to greater acceptance of anti-obesity drugs as appropriate options for treatment. Physicians should be comfortable discussing the risks and benefits of these drugs, and health insurance companies should provide reasonable coverage for their use in patients who are most likely to benefit. Although few promising anti-obesity medications are in the drug-development pipeline, the most promising drugs are novel molecules that are co-agonists for multiple gut hormones including GLP-1, glucagon, and gastric inhibitory peptide.
引用
- Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2017. PMID: 28919062. doi:10.1016/S2213-8587(17)30236-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。